Lively drug shortages in the US climbed to 227 within the second quarter of 2026, the third consecutive quarterly enhance, as a extreme scarcity of the most cancers chemotherapy drug ifosfamide emerged as a result of manufacturing high quality issues and a persistent shortage of CT imaging distinction brokers continued to delay diagnostic procedures at hospitals and imaging facilities throughout the nation. The figures come from the American Society of Well being-System Pharmacists (ASHP) and the College of Utah Drug Info Service, the 2 our bodies which have tracked U.S. drug shortages since 2001.
Whereas 227 energetic shortages is considerably beneath the report of 323 set within the first quarter of 2024, the regular upward pattern of the previous three quarters indicators that the underlying structural vulnerabilities in U.S. pharmaceutical provide haven’t been resolved.
Why This Issues
Drug shortages should not an administrative inconvenience. When a hospital can’t acquire ifosfamide, oncologists treating testicular most cancers or sarcoma should delay healing regimens or substitute much less efficient alternate options. When CT distinction brokers are scarce, radiologists and emergency physicians should ration imaging procedures, doubtlessly delaying most cancers detection, lacking strokes, or deferring cardiac evaluations for sufferers who can’t wait.
“When a drug scarcity entails therapeutic brokers for treating most cancers, the results could possibly be dire, equivalent to elevated treatment errors, hostile results, poor outcomes, and even demise,” because the pharmacy literature on oncology drug shortages has constantly documented. For sufferers awaiting most cancers affirmation, stroke analysis, or diagnostic imaging, shortages translate instantly into delayed diagnoses and care gaps that compound over time.
The scarcity surroundings additionally falls disproportionately on hospital pharmacists, who should find alternate options, coordinate with prescribers to change remedy plans, and doc rationing selections that no patient-facing member of the care staff desires to make.
What We Know So Far
In line with the ASHP Q2 2026 drug scarcity statistics and AJMC evaluation printed July 20, 2026:
The 227 energetic shortages characterize the third consecutive quarterly enhance after a partial restoration from the 2024 peak. Central nervous system medicines are the biggest class of energetic shortages, adopted by antimicrobials, with chemotherapy and hormone brokers tied for third.
Almost half of all new drug shortages in 2026 (48%) contain sole-source merchandise: medicine made by just one producer. This is without doubt one of the most essential structural vulnerabilities in U.S. pharmaceutical provide. When a sole-source producer faces a top quality drawback, contamination discovering, facility shutdown, or provide disruption, there isn’t any backup provider to soak up demand. All the home provide of that treatment disappears concurrently.
Ten % of all new 2026 shortages contain CT and MRI distinction brokers, that are important for a variety of diagnostic procedures together with most cancers staging, stroke analysis, pulmonary embolism analysis, coronary artery imaging, and kidney operate evaluation. Distinction shortages instantly delay or stop these procedures at hospitals that can’t acquire ample provide.
Essentially the most acute new scarcity this quarter is ifosfamide, a chemotherapy drug utilized in healing remedy regimens for testicular most cancers, comfortable tissue sarcoma, and pediatric Ewing sarcoma. The scarcity developed after manufacturing high quality issues surfaced at a key provider. Ifosfamide is utilized in a few of oncology’s most healing contexts: for a lot of males with metastatic testicular most cancers, ifosfamide-containing regimens can obtain long-term remission or remedy even after prior remedy has failed.
Sixteen % of energetic shortages contain managed substances, which instantly impacts sufferers managing continual ache or ADHD, who could battle to fill month-to-month prescriptions, and well being methods that want ample provide for scheduled surgical procedures and procedures.
The place the Impression Is Highest
The distinction agent scarcity hits each hospital and outpatient imaging middle that performs CT or MRI scans. In giant hospital methods, distinction brokers are usually managed by formulary protocols and rationing committees that prioritize probably the most pressing scientific wants. However in smaller hospitals, rural amenities, and neighborhood imaging facilities with much less buying leverage, shortages may end up in outright process cancellations.
The ifosfamide scarcity is concentrated at most cancers facilities and hospitals that deal with testicular most cancers, sarcoma, and pediatric cancers. Oncologists at these establishments are being compelled to judge whether or not substitute regimens are applicable, which regularly means utilizing much less well-studied alternate options or adjusting dosing in ways in which carry their very own threat and uncertainty.
The managed substance scarcity impacts sufferers in continual ache administration packages and people with ADHD who depend upon stimulant medicines, each populations which can be already susceptible to care disruption and for whom treatment gaps carry vital penalties.
What Docs and Consultants Say
“Slightly below half (48%) of all new shortages in 2026 are sole-source merchandise (a single producer),” ASHP famous in its Q2 information abstract. “Ten % of all new shortages in 2026 are distinction brokers used for doubtlessly life-saving procedures equivalent to CT scans and MRIs.”
The ASHP has constantly argued that the basis explanation for drug shortages is structural: the generic injectable drug market is organized in ways in which undervalue provide resilience, reward cost-cutting over redundancy, and create situations the place a single producer disruption can cascade right into a nationwide scarcity. The financial framework for generic drug manufacturing doesn’t robotically incentivize the form of manufacturing range and reserve capability that will stop a sole-source disruption from eliminating nationwide provide.
ASHP has advisable congressional motion to create monetary incentives for multi-source manufacturing of important medicines, set up strategic reserves for essential shortage-prone medicine, and strengthen FDA oversight of producing high quality at generic amenities.
What the Proof Reveals and What It Does Not
MedicalDaily Proof Test
Knowledge supply: ASHP (American Society of Well being-System Pharmacists) and College of Utah Drug Info Service Q2 2026 drug scarcity statistics
Lively shortages (Q2 2026): 227 — the third consecutive quarterly enhance
All-time excessive (comparability): 323 in Q1 2024
2024 year-end comparability: 271 at finish of 2024
Notable new scarcity: Ifosfamide (chemotherapy for testicular most cancers and sarcoma) — extreme, as a result of manufacturing high quality issues at a key provider
Sole-source proportion of latest 2026 shortages: 48%
Distinction agent proportion of latest 2026 shortages: 10%
Managed substance proportion of energetic shortages: 16%
What it exhibits: An energetic, upward-trending drug scarcity surroundings with particular acute shortages in high-stakes oncology and diagnostic imaging classes
What it doesn’t present: Hospital-by-hospital provide ranges, affected person hurt statistics instantly attributed to the present scarcity interval, or timeline for decision of particular shortages
What readers ought to know: Sufferers who’re presently on or anticipating to start out ifosfamide-containing regimens, or whose doctor has ordered CT with distinction, ought to converse with their care staff about present availability and any deliberate alternate options.
Who Is Most Affected?
The sufferers dealing with probably the most direct hurt from present shortages embrace:
Most cancers sufferers awaiting or presently on ifosfamide-containing healing chemotherapy regimens (testicular most cancers, sarcoma, Ewing sarcoma)
Sufferers requiring CT or MRI with distinction for most cancers staging, stroke analysis, cardiac imaging, or pulmonary embolism evaluation
Sufferers managing continual ache who depend upon managed substance prescriptions that will face delays
Folks with ADHD whose stimulant treatment prescriptions could also be tough to fill
Any affected person whose doctor has prescribed a medicine in energetic scarcity and who has already encountered problem acquiring it
What You Can Do Now
In case you are a most cancers affected person whose remedy plan contains ifosfamide, ask your oncologist or infusion pharmacy instantly about present availability and whether or not there’s a substitute routine being ready as a contingency.
In case you have been informed {that a} CT or MRI with distinction is being delayed as a result of provide, ask your doctor whether or not the delay poses a scientific threat that must be escalated, or whether or not another imaging modality (equivalent to MRI with out distinction or ultrasound) can present comparable scientific info within the interim.
Should you take a managed substance for continual ache or ADHD, contact your pharmacy and prescriber at the least every week prematurely of your month-to-month refill to permit time for different sourcing if wanted.
Healthcare suppliers experiencing particular drug shortages can entry present alternate options and administration steerage by the ASHP drug scarcity database and the College of Utah Drug Info Service.
Sufferers who need to report a scarcity influence to federal officers can contact the FDA’s drug scarcity employees or their congressional representatives, who’ve the authority to direct FDA to analyze or prioritize scarcity decision.
Value and Entry: What Sufferers Ought to Know
Drug shortages generally lead hospitals to make use of different brokers which can be costlier, much less well-studied, or not coated by the affected person’s insurance coverage below the identical phrases because the initially prescribed drug. Sufferers who’re switched to another treatment as a result of scarcity ought to ask their prescriber to doc the substitution and speak to their insurance coverage plan to substantiate protection of the substitute earlier than the primary administration.
For most cancers sufferers whose remedy is being altered as a result of ifosfamide scarcity, affected person advocacy organizations together with the American Most cancers Society and the Testicular Most cancers Consciousness Basis might be able to present navigation help and data on different sourcing choices.
What Occurs Subsequent
The ifosfamide scarcity will likely be pushed by the restoration timeline of the producer’s high quality remediation, which isn’t publicly disclosed. ASHP and the FDA Drug Scarcity Employees are anticipated to supply periodic updates. Distinction agent shortages are ongoing and pushed by each provide and demand dynamics which have endured because the 2022 preliminary scarcity; decision requires new manufacturing capability or demand discount methods that take months to implement. MedicalDaily will report on scarcity decision bulletins and any vital new entries to the energetic scarcity checklist.
The Backside Line
U.S. drug shortages rose to 227 within the second quarter of 2026, the third consecutive quarterly rise, with a extreme new scarcity of the testicular most cancers and sarcoma chemotherapy drug ifosfamide, ongoing shortage of CT and MRI distinction brokers affecting diagnostic imaging, and protracted managed substance shortages for continual ache and ADHD sufferers. The underlying trigger is structural: practically half of all new shortages contain medicine made by just one producer, and a single facility’s high quality failure eliminates nationwide provide with no quick backup. Sufferers on affected medicines ought to converse with their care staff about contingency planning now.
